By partnering with TransPharMed, OncoLens was able to grow an additional $1MM in revenue over the course of 16 months. In addition, TransPharMed refined our messaging strategy for key decision making personas across community based hospitals, academic health systems, integrated delivery networks (IDNs) and biopharmaceutical customers. Critical to the long term business of OncoLens, TransPharMed secured the first NCI Designated Cancer Center, The James Cancer Center at Ohio State University as a customer. This win was significant because it validated a new value proposition and business model that will be a template for future similar customer. By developing relationships with decision makers in a short amount of time, TransPharMed also expanded the OncoLens business by 10 fold within one of the largest IDNs in the country, Ascension Health. The work that TransPharMed did for OncoLens has helped to build a selling foundation for our success in the future.